NEW YORK (GenomeWeb News) – The New York Stem Cell Foundation (NYSCF) Research Institute and PersonalGenomes.org on Monday announced they are partnering to identify genetic and environmental factors in trait and disease development.
For early adopters, there are many reasons to be excited about the potential of whole-genome sequencing to broadly personalize healthcare. But for some public health observers, the analytical and educational challenges present an overwhelming hurdle.
Since a US federal district court last month deemed seven of Myriad Genetics' BRCA patents invalid, certain industry players have taken small steps toward fostering more collaboration around gene patents while others have raised questions about the value of patenting genes altogether amid rapid advances in whole-genome sequencing.
In a newsletter published last week, PGP organizers said they have now started to enroll participants for the PGP-100. Enrollment for the next phase of the project, PGP-1000, is expected to start later this year.
Whether the project will adopt whole-genome sequencing instead of exome sequencing will depend on factors such as its ability to raise funding and "the willingness of sequencing companies to publicly showcase their technologies through sponsorship of PGP-100 genomes."